Ohio Colleges of Medicine Government Resource Center, Ohio State University Medical Center, United States of America.
Tri-State Maternal-Fetal Medicine Associates, United States of America.
J Subst Abuse Treat. 2019 Jul;102:53-59. doi: 10.1016/j.jsat.2019.04.010. Epub 2019 May 2.
A collaborative led by state health and human service agencies, academic leaders, and stakeholders tested interventions to expand use of medication assisted treatment (MAT) through a maternal medical home (MMH) model that coordinated behavioral health and prenatal care with social supports for pregnant women with opioid use disorder (OUD) enrolled in Medicaid. The program was anchored in four clinical organizations with distinct models of care: community behavioral health, residential behavioral health, hospital-based obstetrical practice, and co-located obstetrical and behavioral health. A modified version of the Institute for Healthcare Improvement Breakthrough Series Model for Improvement was implemented using monthly performance data feedback to conduct small tests of change and improve care. Administrative data from the state's Medicaid, vital statistics, and child welfare systems were linked to evaluate the impact of MOMS on 252 mother-infant dyads compared to a sample of 846 Medicaid beneficiaries with OUD in the third trimester of pregnancy. MOMS participation was associated with increased likelihood of MAT in trimesters one, two and three (AOR = 2.30, 4.40, 2.75, respectively), behavioral health counseling during trimesters two and three (AOR = 3.75 and 2.07, respectively), retention in MAT during postpartum months one through three and four through six (AOR = 2.86, 2.40, respectively), and marginally lower out-of-home placement of infants born to mothers with OUD (AOR = 0.66). Within the MOMS program, greater participation in behavioral health treatment and MAT (χ(3) ≥ 12.09) was observed in the co-located behavioral health/obstetrical care practice site compared to behavioral health-led and obstetrical provider-led sites.
一个由州卫生和人类服务机构、学术领袖和利益相关者领导的合作项目,测试了通过产妇医疗之家 (MMH) 模式扩大药物辅助治疗 (MAT) 应用的干预措施,该模式协调了行为健康和产前护理,以及为参加医疗补助计划的患有阿片类药物使用障碍 (OUD) 的孕妇提供社会支持。该项目以四个具有不同护理模式的临床组织为基础:社区行为健康、住院行为健康、基于医院的产科实践和产科与行为健康共存。使用月度绩效数据反馈实施了改进版的医疗保健改进研究所突破性系列改进模式,以进行小规模的变革测试和改善护理。从该州的医疗补助、生命统计和儿童福利系统中获取行政数据,以评估 MOMS 对 252 对母婴对与在妊娠晚期患有 OUD 的 846 名医疗补助受益人的影响。MOMS 的参与与 MAT 在第一、第二和第三孕期的可能性增加有关(AOR=2.30、4.40、2.75),第二和第三孕期的行为健康咨询(AOR=3.75 和 2.07),产后 1 至 3 个月和 4 至 6 个月的 MAT 保留率(AOR=2.86、2.40),以及 OUD 母亲所生婴儿的家庭外安置率略有降低(AOR=0.66)。在 MOMS 项目中,与行为健康主导和产科提供者主导的地点相比,在产科和行为健康共存的护理实践地点观察到更多的行为健康治疗和 MAT 参与(χ(3)≥12.09)。